en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
5/2020
vol. 58
 
Share:
Share:
more
 
 
abstract:
Review paper

Liver involvement in rheumatic diseases

Joanna Podgórska
1
,
Paulina Werel
1
,
Jakub Klapaczyński
1
,
Dorota Orzechowska
1
,
Mariusz Wudarski
2
,
Andrzej Gietka
1

1.
Department of Internal Diseases and Hepatology, Central Clinical Hospital of Ministry of the Interior and Administration, Warsaw, Poland
2.
Systemic Connective Tissue Diseases Clinic and Polyclinic, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
Reumatologia 2020; 58, 5: 289–296
Online publish date: 2020/10/13
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Liver involvement in rheumatic diseases may occur as a primary liver disease, primary rheumatic disease with hepatic manifestations or antirheumatic drug-induced liver disease. The aim of our article is to underline the importance of monitoring and control of the level of aminotransferases and cholestatic enzymes in rheumatic disorders. Some of the rheumatic diseases with constantly elevated liver enzymes need to be investigated in consideration of concomitant primary autoimmune liver disease (such as autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis) or drug hepatotoxicity. Also, we should be aware of hepatitis B reactivation or hepatitis C flare when immunosuppressants are used.
keywords:

liver, autoimmune, rheumatic diseases







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.